From Patterson's 19 June 09 Research Note (page 10):
A study by Czerepak et Ryser established a biotech failure rate of 74% (although we would make the
observation that aspects of the treatment have been significantly de-risked, as a result of the current
widespread use of Artmether in tablet form). This implies a risk adjusted value for Eastland® of $0.26.
If phase III trials are successful and after other appropriate submissions (below uses FDA approvals
as a proxy albeit not relevant for ArtiMistTM), then Eastland® valuation would rise to ~$1.50 on a derisked
commercialised basis.
- Forums
- ASX - By Stock
- pre trial npv of 26c
From Patterson's 19 June 09 Research Note (page 10):A study by...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EMS (ASX) to my watchlist
|
|||||
Last
2.8¢ |
Change
-0.002(5.08%) |
Mkt cap ! $3.182M |
Open | High | Low | Value | Volume |
3.0¢ | 3.0¢ | 2.8¢ | $5.519K | 184.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 149957 | 2.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.0¢ | 89144 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 149957 | 0.028 |
1 | 370370 | 0.027 |
2 | 166552 | 0.021 |
2 | 175250 | 0.020 |
1 | 30000 | 0.019 |
Price($) | Vol. | No. |
---|---|---|
0.030 | 89144 | 1 |
0.032 | 138055 | 1 |
0.033 | 269912 | 1 |
0.035 | 249968 | 1 |
0.036 | 100000 | 1 |
Last trade - 14.39pm 10/09/2024 (20 minute delay) ? |
Featured News
EMS (ASX) Chart |